Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN11 | Q06124 | 1/20 | 0.57 |
| ▸ | GPR119 | Q8TDV5 | 10/20 | 0.48 |
| ▸ | ACHE | P22303 | 2/20 | 0.48 |
| ▸ | MAPT | P10636 | 2/20 | 0.47 |
| ▸ | CKS1B | P61024 | 2/20 | 0.45 |
| ▸ | SKP1 | P63208 | 2/20 | 0.45 |
| ▸ | SKP2 | Q13309 | 2/20 | 0.45 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.44 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25252203 | 1.00 | PTPN11 (0.57) | PTPN11GPR119ACHEMAPTCKS1B | |
| SCHEMBL30422517 | 0.90 | PTPN11 (0.58) | PTPN11GPR119ACHEMAPTCKS1B | |
| SCHEMBL22006096 | 0.83 | PTPN11 (0.58) | PTPN11GPR119ACHEMAPTCKS1B | |
| SCHEMBL25215112 | 0.81 | PTPN11 (0.52) | PTPN11GPR119ACHEMAPTCKS1B | |
| SCHEMBL3607189 | 0.81 | GPR119 (0.57) | PTPN11GPR119ACHEMAPTCKS1B | |
| SCHEMBL16333807 | 0.81 | MAP4K4 (0.52) | PTPN11GPR119MAPTCKS1BSKP1 | |
| SCHEMBL27316944 | 0.80 | POLB (0.55) | PTPN11MAPTSMN1; SMN2 | |
| SCHEMBL25216474 | 0.79 | PTPN11 (0.56) | PTPN11GPR119ACHEMAPTCKS1B | |
| SCHEMBL30422622 | 0.79 | PTPN11 (0.56) | PTPN11GPR119ACHEMAPTCKS1B | |
| SCHEMBL25244358 | 0.78 | PTPN11 (0.48) | PTPN11GPR119ACHEMAPTCKS1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250122192-A1 | 5-PYRIMIDINECARBOXAMIDE DERIVATIVES AND METHODS OF USING THE SAME | RGENTA THERAPEUTICS, INC. | 2025-04-17 | — | — | US | disclosed |
| EP-4441042-A1 | 5-PYRIMIDINECARBOXAMIDE DERIVATIVES AND METHODS OF USING THE SAME | Rgenta Therapeutics, Inc. (US) | 2024-10-09 | — | — | EP | disclosed |
| CN-118748995-A | 5-Pyrimidine carboxamide derivatives and methods of use thereof | 亚根达医疗公司 | 2024-10-08 | — | — | CN | disclosed |
| WO-2023102231-A1 | 5-PYRIMIDINECARBOXAMIDE DERIVATIVES AND METHODS OF USING THE SAME | RGENTA THERAPEUTICS, INC. (US) | 2023-06-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250122192-A1 | 5-PYRIMIDINECARBOXAMIDE DERIVATIVES AND METHODS OF USING THE SAME | RTCB, NSUN2, PRPF19 | PTPN11 4344/4885GPR119 1285/4885ACHE 4724/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.